[Differentiation of HL-60 cells induced by realgar nano-particles].
OBJECTIVE
To investigate the proliferation inhibition and the differentiation effects of realgar (As4S4) nano-particles on human acute myeloid leukemia cell line HL-60.


METHODS
Cell viability was determined by MTT and PI-stained cell cycle assays. The realgar induced morphological changes on cells were examined after Wright-Giemsa staining. The cell differentiation was evaluated with NBT and specific cell surface antigen (CD11b and CD14) expression assays.


RESULTS
HL-60 cells exhibited obvious morphological features of differentiation after the realgar treatment. A 24 h incubation of the cells with 0.25-1.0 micromol x L(-1) realgar caused a great increase in NBT reduction ability. The expressions of CD11b and CD14 were augmented in cells treated with 0.50 micromol x L(-1) realgar for 48 h, and cell cycles were arrested in G1 phase.


CONCLUSIONS
Low dose realgar induces differentiation in human acute myeloid leukemia cell line HL-60.
Luo
Li-Yun
LY
Peking University School of Pharmaceutical Sciences, Beijing 100083, China.
Zhang
Tian-Lan
TL
Wang
Kui
K
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001152:Arsenicals / Q000008:administration & dosage* / Q000494:pharmacology; D039481:CD11b Antigen / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D016193:G1 Phase / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D008419:Materia Medica / Q000008:administration & dosage* / Q000494:pharmacology; D053758:Nanoparticles; D013440:Sulfides / Q000008:administration & dosage* / Q000494:pharmacology
D000970:Antineoplastic Agents; D001152:Arsenicals; D039481:CD11b Antigen; C509295:ITGAM protein, human; D018950:Lipopolysaccharide Receptors; D008419:Materia Medica; D013440:Sulfides; C058317:arsenic disulfide